论文部分内容阅读
目的观察利拉鲁肽联合二甲双胍治疗2型糖尿病的临床效果。方法选取医院收治的85例血糖控制不佳的2型糖尿病患者作为研究对象,均停用原有降糖方案中除二甲双胍以外所有降糖药物并加用利拉鲁肽治疗,疗程为3个月。比较患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)变化及治疗3个月后患者体质量指数(BMI)、收缩压(SBP)、舒张压(DBP)、血清总胆固醇(TC)、三酰甘油(TG)变化情况。结果治疗后,患者FBG、2 hPG和HbA1c较治疗前均降低,且BMI、SBP、DBP、TC及TG较治疗前也均降低,差异有统计学意义(P均<0.05)。结论对于血糖控制不佳的2型糖尿病患者使用利拉鲁肽治疗可有效降低血糖,具有减轻体质量,降低血压血脂的效果,值得临床推广应用。
Objective To observe the clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus. Methods Totally 85 patients with type 2 diabetes with poor glycemic control admitted to hospital were enrolled in this study. All antidiabetic drugs other than metformin except for metformin were stopped and treated with liraglutide. The course of treatment was 3 months . The changes of fasting blood glucose (FBG), 2 h postprandial blood glucose (2 hPG) and HbA1c before and after treatment and the changes of body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) ), Serum total cholesterol (TC), triglyceride (TG) changes. Results After treatment, the FBG, 2 hPG and HbA1c in patients were lower than those before treatment, and the BMI, SBP, DBP, TC and TG were also lower than those before treatment, the difference was statistically significant (all P <0.05). Conclusion The treatment of liraglutide in type 2 diabetic patients with poorly controlled blood glucose can effectively reduce blood sugar, reduce body weight and blood pressure, and is worthy of clinical application.